Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo

Junya Masumoto,1 Kangkang Yang,1 Sooryanarayana Varambally,1 Mizuho Hasegawa,1 Scott A. Tomlins,1 Su Qiu,1 Yukari Fujimoto,4 Akiko Kawasaki,5 Simon J. Foster,5 Yasuo Horie,6 Tak W. Mak,6 Gabriel Núñez,1,2 Arul M. Chinnaiyan,1,3 Koichi Fukase,2 and Naohiro Inohara1

1Department of Pathology, 2Comprehensive Cancer Center, and 3Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109
2Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
3Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, England, UK
4Department of Pathology, 5Comprehensive Cancer Center, and 6Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109
5Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, England, UK
6Advanced Medical Discovery Institute, Ontario Cancer Institute and Department of Medical Biophysics and Immunology, University of Toronto, Toronto, Ontario, M5G 2C1, Canada

Nod1 is a member of family of intracellular proteins that mediate host recognition of bacterial peptidoglycan. To characterize immune responses mediated by Nod1, synthetic ligand compounds possessing enhanced ability to stimulate Nod1 were developed to study the function of Nod1. Stimulation of epithelial cells with Nod1 stimulatory molecules induces chemokines and other proinflammatory molecules that are important for innate immune responses and recruitment of acute inflammatory cells. Administration of Nod1 ligands into mice induced chemokines and recruitment of acute inflammatory cells, an activity that was abolished in Nod1–null mice. Microarray analysis revealed that Nod1 stimulation induces a restricted number of genes in intestinal epithelial cells compared with that induced by tumor necrosis factor (TNF) α. Nod1 stimulation did not induce TNFα, interleukin 12, and interferon γ, suggesting that the primary role of Nod1 is to induce the recruitment of immune cells. These results indicate that Nod1 functions as a pathogen recognition molecule to induce expression of molecules involved in the early stages of the innate immune response.

Recognition of bacterial components by host-specific molecules is the first step in the defense against invading bacteria (1). In the initial encounter with pathogenic bacteria, epithelial surfaces provide a physical barrier but also produce several molecules that are microbicidal or that inhibit bacterial growth (1). A second line of defense is mediated through host cellular receptors that recognize molecules uniquely expressed by bacteria, and upon activation they induce innate and adaptive immune responses to effectively eliminate the invading microbe. Toll-like receptors (TLRs) are a major class of host molecules that are activated by microbial products, including LPS, lipoproteins, and bacterial DNA (1, 2). In addition to TLRs that recognize bacterial ligands at the plasma membrane and luminal side of intracellular vesicles, a family of proteins called Nods, or Caterpiller, provide sensing of bacteria in the cytosol (2–4). The Nod protein family is comprised more than 20 members, including Nod1, Nod2, Cryopyrin, and Ipaf. The majority of Nod proteins are composed of an amino-terminal effector domain involved in downstream signaling, a centrally located nucleotide-binding oligomerization domain, and carboxyl-terminal leucine-rich repeats.

Nod1 is the founding member of the Nod protein family, which is expressed in multiple tissues and cells, including intestinal epithelia (2, 5). The core structure of the ligand recognized by Nod1 is a peptidoglycan (PGN)-specific dipeptide, γ-D-glutamyl–meso-diaminopimelic acid (AcAiQ), which is a reactive dipeptide released upon bacteria lysis (2). Nod1 stimulation does not induce proinflammatory cytokines and chemokines in intestinal epithelial cells (5). The core structure of the ligand is recognized by Nod1 is a peptidoglycan (PGN)-specific dipeptide, γ-D-glutamyl–meso-diaminopimelic acid (AcAiQ), which is a reactive dipeptide released upon bacteria lysis (2). Nod1 stimulation does not induce proinflammatory cytokines and chemokines in intestinal epithelial cells (5).
acid (iE-DAP), which exists as insoluble PGN, soluble PGN fragments, and intermediates produced during PGN biosynthesis (6, 7). There is evidence that Nod1 mediates host recognition of bacteria or bacterial fractions containing soluble PGN-related molecules with the essential iE-DAP dipeptide (8–12). Upon recognition of its bacterial ligand, Nod1 induces activation of NF-κB and mitogen-activated protein kinase, two signaling pathways that are involved in cellular responses against bacteria (5–13). Activation of intracellular signaling through Nod1 is mediated by RICK, a caspase recruitment domain–containing kinase that interacts with Nod1 (5, 13–15). However, the immune responses elicited by Nod1 stimulation are poorly characterized.

Bacteria containing Nod1 stimulatory molecules also possess TLR ligands, including LPS, that induce innate immune responses in host cells (1). There is evidence that Nod and TLR proteins act cooperatively to modulate innate immune responses against bacteria. For example, stimulation of Nod1 alone induces the secretion of very low levels of IL-6 and TNFα in macrophages, but the response is greatly enhanced by co-stimulation with LPS (6). Recent reports also suggest that Nod1 plays a role in intestinal immunity by regulating innate immune responses of epithelial cells infected with invasive enterobacteria and Helicobacter pylori (10, 11). The intestinal lumen contains a large number of resident bacteria that live in a symbiotic relationship with the host (16). Commensal bacteria express a wide array of stimulatory TLR ligands, but the organism has developed mechanisms to avoid innate recognition and harmful inflammatory responses at intestinal sites (17). These include a lack or low levels of TLRs such as TLR2 and TLR4 in intestinal epithelial cells and expression of molecules that inhibit TLR signaling (17). Given that Nod1 is functionally expressed in intestinal epithelial cells (5, 9, 10, 18), we hypothesized that stimulation of Nod1 by bacterial products might be sufficient to induce immune responses that are important for host defense against invading bacteria. In this paper, we demonstrate that stimulation of cultured cells and mice with bacterial products containing the essential iE-DAP dipeptide induces innate immune responses in a Nod1-dependent manner.

RESULTS

Addition of peripheral structures to the core dipeptide recognized by Nod1 does not result in increased stimulatory activity

Stimulation of host cells by iE-DAP alone induces very low levels of IL-6 and TNFα secretion (6). Furthermore, high doses of iE-DAP, compared with TLR ligands, are required to induce chemokines in intestinal epithelial SW620 and oral epithelial HSC–2 cells (19, 20). The high dose of Nod1 ligand required for Nod1 stimulation has hampered the analysis of Nod1-mediated immune responses in vitro and in vivo. To circumvent this problem, we sought to develop synthetic compounds that possess an enhanced ability to stimulate Nod1. Previous reports suggest that the peripheral structures of iE-DAP–containing molecules (Fig. 1 A) affect their ability to stimulate Nod1 (6, 7). Therefore, we initially characterized the structural requirement for Nod1 stimulatory activity using a published bioassay with human embryonic kidney (HEK) 293T cells transiently expressing Nod1 (6). The monomer disaccharide tetrapeptide N-acetyl-glucosamyl (GlcNAc)–N-acetyl-muramyl (MurNAc)–l-Ala–γ-d-Glu–meso-DAP–d-Ala was Nod1 stimulatory, whereas the dimeric disaccharide dipeptide resulting from one linkage between the ε-amino residue in mesoDAP and the α-carboxyl residue in d-Ala was not (Fig. 1 B). We also found that the stimulatory activity of the tripeptide l-Ala–γ-d-glutaminyl–meso-DAP (iQ-DAP) was less than the dipeptide iQ-DAP (Fig. 1 C). These results indicate that NH2-terminal peptide expansion of the core dipeptide recognized by Nod1 does not result in higher stimulatory activity.

Development of synthetic compounds with high Nod1 stimulatory activity

Based on the results given in Fig. 1, we used the dipeptide iE-DAP as a seed structure to develop compounds with an enhanced ability to stimulate Nod1. Consistent with cytotoxic localization of Nod1 (5), microinjection or calcium phosphate–mediated incorporation of Nod1 ligands into cells enhances the ability of the ligands to stimulate Nod1 (6, 8, 12). Furthermore, H. pylori is reported to inject Nod1 ligand through a type IV secretion system into host cells (11). These observations suggest that hydrophobic acylation of Nod1 ligands may improve their membrane permeability and ability to stimulate Nod1. To test this hypothesis, we developed synthetic compounds containing various acyl residues at the NH2 terminus of iE-DAP (X1 in Fig. 1 A). N-myristoyl (C-14) iE-DAP, designated here as KF1B, as well as other acyl iE-DAP compounds (not depicted) were found to specifically stimulate Nod1 (Fig. 2 A), but not Nod2 or TLR4/MD-2, signaling using the HEK293T bioassay (Fig. 2 B). These results indicate that acylation of the iE-DAP dipeptide does not affect ligand recognition or receptor specificity. Further analysis showed that KF1B exhibited a several hundredfold higher ability to induce Nod1-dependent NF-κB activation than the original dipeptide iE-DAP, as determined by the amount of compound required for achieving 50% of maximum activity (Fig. 2 A). Testing of additional compounds revealed that pentadecanoyl (referred as KFC15; C-15) and palmitoyl (referred as KFC16; C-16) iE-DAP also possessed a similar ability to stimulate Nod1 as KF1B (unpublished data). Although efficient stimulation of Nod1 by natural ligands requires the coexistence of calcium phosphate particles under our culture conditions (6, 8), we found that KF1B no longer requires calcium phosphate particles to stimulate Nod1 signaling, which was consistent with our hypothesis that the enhanced ability of KF1B to stimulate Nod1 is caused by increased accessibility to the cytosol (Fig. 2 C).
ARTICLE

Nod1-dependent enhancement of LPS-induced cytokine secretion by KF1B in macrophages and DCs

To determine if KF1B enhances LPS-induced cytokine production through endogenous Nod1, human monocytic MonoMac6 cells that express Nod1 were stimulated with the iE-DAP–derived compounds and controls. Stimulation of MonoMac6 cells with KF1B alone at concentrations as high as 2,500 ng/ml induced neither the secretion of IL-6 nor IL-1β (Fig. 3, A and B). However, KF1B possessed a higher ability to enhance LPS-induced production of these cytokines compared to iE-DAP alone.

Figure 1. Structures of core Nod1 ligand and the effects of amino acid modifications on the Nod1 stimulatory activity. (A) Core structure of Nod1 ligand. The structure of core Nod1 ligand iE-DAP is shown with its peripheral residues (X1 to X4). The activity of the Nod1 ligand without modification is given as one unit. The tripeptide in C and D contain L-Ala at the X1 position; KF1B, KFC15, and KFC16 have myristoyl [CH₃(CH₂)₁₄-C=O], pentadecanoyl [CH₃(CH₂)₁₅-C=O], and palmitoyl [CH₃(CH₂)₁₄-C=O], respectively, at the X1 position. iQ-DAP has amino residue at the X2 position; a cross-bridge to another PGN chain occurs at X3. The amino residues at the X3 position varies dependent on the bacterial species and composition of PGN intermediates. (B) Nod1 stimulatory activity of purified PGN fragments from B. subtilis. 10⁵ HEK293T cells were transfected with the Nod1 expression plasmid together with NF-κB–dependent and –independent reporter plasmids as described previously (reference 4). 8 h after transfection, cells were treated with the indicated amounts of whole soluble Cellosyl-treated PGN fragments.

Figure 2. Development of synthetic acyl Nod1 ligands. (A) Enhanced ability of synthetic acyl compound KF1B to stimulate Nod1. HEK293T cells were transfected with the Nod1 expression plasmid. 8 h after transfection, cells were treated with the indicated amounts of the ligand. 24 h after transfection, NF-κB–dependent transcription activity was determined. (B) Nod1-dependent NF-κB activation induced by the acyl Nod1 ligands. HEK293T cells were transfected with the expression plasmid of Nod1, Nod2, or TLR4 and MD2 (TLR4/MD2) or control vector (−). 8 h after transfection, cells were treated with the indicated amounts of synthetic iE-DAP or iQ-DAP (L-Ala–iE-DAP–D-Ala). 24 h after transfection, NF-κB–dependent transcription activity was determined. (C) Requirement of calcium phosphate particles for iE-DAP, but not KF1B, to stimulate Nod1. HEK293T cells were first transfected with Nod1 expression plasmid and reporter constructs. 8 h after transfection, calcium phosphate particles were removed by changing the medium. 9 h after transfection, the cells were stimulated with 1 ng/ml Nod1 ligands, iE-DAP, and KF1B in the absence and presence of calcium phosphate particles. 24 h after transfection, NF-κB–dependent transcription activity was determined. The results shown in the figures are given as means ± SD of triplicate cultures and are representative of five experiments.
cytokines than the original iE-DAP (Fig. 3, A and B). KF1B was effective in stimulating LPS-induced responses at concentrations as low as 25 ng/ml and was comparable to MurNAc-l-Ala-γ-γ-Glu-l-Lys(stearyl)-OH (AcMTP), a modified ligand of Nod2 (21–23). As observed with MonoMac6 cells, stimulation of BM-derived mouse macrophages and DCs with KF1B alone did not induce the secretion of CCL2/MCP-1 (Fig. 3 C), IL-1β, and IL-12 (not depicted). However, KF1B enhanced LPS-induced CCL2 secretion from DCs (Fig. 3 C) and IL-6 secretion from macrophages (Fig. 3 D). Notably, the response of macrophages with KF1B was abolished in Nod1-deficient macrophages (Fig. 3 D), demonstrating that KF1B requires Nod1 for enhancement of CCL2 secretion.

Nod1 stimulation through KF1B induces chemokine expression and NF-κB activation in intestinal epithelial cells

Given that Nod1 is expressed in the intestinal epithelium, we tested whether KF1B alone can induce cellular responses in epithelial cells. We found that KF1B alone, but not meso-DAP, induced production of IL-8 in two human intestinal epithelial cell lines, LoVo and SW620 (Fig. 4, A–C). In contrast, LoVo cells did not respond after stimulation with LPS, CpG, and polyIC (Fig. 4, A and B), which was consistent with the lack of TLR signaling in most intestinal epithelial cells (17). In addition, KF1B induced NF-κB in LoVo cells as determined with an NF-κB–dependent reporter assay (Fig. 4 D). ELISA, real-time PCR, and immunoblotting analyses showed that KF1B also induced CXCL1/Groα and CD83, two molecules that are important for the recruitment and interaction of immune cells (Fig. 4, E–G).

Nod1 and TNF-α stimulation induced common and specific gene induction in epithelial cells

To further characterize events induced by Nod1 stimulation in LoVo intestinal cells, we determined global gene expression changes using a cDNA microarray containing ~20,000 genes (Table I). At 60 min after stimulation, KF1B induced 11 genes at >2-fold and 41 genes at >1.6-fold as compared with unstimulated cells (Table I). Further analysis at 3 and 24 h after stimulation revealed induction of 6 and 17 genes at >1.6-fold levels, respectively. The intestinal epithelium is the first line of defense against invasive bacteria and mediates innate immune responses, at least in part through TNFα. Therefore, we next examined the gene expression profile induced by KF1B and TNFα in LoVo cells. TNFα induced 37 genes at >1.6-fold levels at 1 h after stimulation (Table I). Notably, 11 of these genes induced by TNFα stimulation were also induced by KF1B (Table I). The great majority of genes induced by both KF-1B and TNFα are known to be up-regulated through NF-κB and proinflammatory molecules (Table I), which is consistent with the observation that KF1B and TNFα induce gene expression through NF-κB signaling. The genes induced by KF1B and TNFα included molecules involved in innate immune responses (CXCL1, MBL2, and CD83) and negative feedback regulators of inflammatory and apoptotic pathways (NFKBIA/IκBα, ATF3, TNFAIP3/A20, CFLAR/CLARP, and BIRC3/c-IAP2). Transient induction of CXCL1 mRNA in the early stage of Nod1 stimulation is consistent with the ability of KF1B to induce CXCL1 secretion (Fig. 4 E). Nod1 stimulation did not induce proinflammatory cytokines, including TNFα and IL-1s, suggesting that Nod1 mediates a restricted pattern of immune responses. The microarray results also revealed a
A group of genes that are induced specifically by Nod1 or TNFα stimulation. 31 genes were induced by Nod1 but not TNFα stimulation. These genes included signaling molecules of TLR and IL1R pathways (MAP3K7/TAK1 and MAIL/IκBζ), components of ubiquitin/proteasome pathway (UBE2M, UBE2D3, RYBP, and WSB1) and 6 novel genes, whereas TNFα stimulation induced 37 unique genes including signaling molecules of Ephrin pathways (EFNA1 and EPHA2), transcription factors (EGR1, FOSL2/Fra2, and ELF3), and innate immune factors (PLAU/plasminogen activator and TNFAIP2a; Table I). These results suggest that Nod1 and TNFα mediate unique and overlapping innate immune responses in epithelial cells.

Nod1 stimulation induces chemokine production and neutrophil recruitment in vivo

To test whether KF1B mediates Nod1-dependent immune responses in vivo, we stimulated WT and Nod1-deficient mice with KF1B i.p. and measured production of chemokines and cytokines in the animals. Administration of KF1B induced rapid production of CCL2 (Fig. 5 A) and CXCL1/Größ in the serum (Fig. 5 B). KF1B was as effective as LPS or MDP in inducing secretion of CCL2 (Fig. 5 A). Notably, serum secretion of CCL2 in response to KF1B was abolished in Nod1-deficient mice (Fig. 5 A), indicating that production of CCL2 is totally dependent on Nod1 in vivo. The lack of response of Nod1-deficient mice was specific in that they produced CCL2 after administration of LPS or MDP (Fig. 5 A). Because Nod1 is highly expressed in airways and the intestine (5), we also tested whether intranasal and oral administration of KF1B could induce immune responses. Consistent with the expression of Nod1 in these organs, production of CCL2 was induced in WT mice but not in Nod1-deficient mice after intranasal and oral administration of KF1B (Fig. 5 C). In contrast to the production of chemokines, administration of KF1B did not induce secretion of IFN-γ, IL-3, CSF2 (M-CSF), IL-12 (Fig. 5 D), and IL-4, -10, -18, and -1β (not depicted) in the serum or tissues, including spleen, liver, and kidney, when compared with the levels found in control mice (Fig. 5 D). Further analysis did not reveal any production of these cytokines at 24 h after Nod1 stimulation (unpublished data), suggesting that the lack of response is not caused by delayed production of these cytokines. These findings are consistent with our results in vitro that Nod1 stimulation induces a restricted number of immune response genes. Because Nod1 stimulation induced chemokine secretion in vitro and in vivo, we next tested whether Nod1 stimulation can induce recruitment of specific...
| Gene     | Fold | Gene     | Fold | Gene     | Fold | Gene     | Fold |
|----------|------|----------|------|----------|------|----------|------|
| NFKBIA   | 3.45 | NFKBIA   | 10.53| BIRC3    | 3.28 | P4HA1    | 2.02 |
| CXCL1    | 2.67 | CLTCL1   | 5.37 | NFKBIA   | 3.00 | Novel    | 1.92 |
| CFLAR    | 2.42 | TNFAIP3  | 5.12 | CD83     | 1.96 | BNIP3L   | 1.91 |
| SKI      | 2.25 | CXCL1    | 4.68 | TNFAIP3  | 1.85 | Novel    | 1.90 |
| HNRPC    | 2.25 | Unknown  | 4.35 | MBL2     | 1.78 | HSD11B2  | 1.85 |
| NUP43    | 2.13 | MBL2     | 4.24 | VPS13A   | 1.62 | ANGPTL4  | 1.84 |
| AHCYL1   | 2.04 | BIRC3    | 4.07 |          |      | Novel    | 1.82 |
| HIPK3    | 2.04 | SKI      | 3.98 |          |      | ANGPTL4  | 1.81 |
| ATF3     | 2.03 | MCF2     | 3.51 |          |      | WSB1     | 1.76 |
| RYBP     | 2.02 | Novel    | 2.92 |          |      | GBE1     | 1.76 |
| TCERG1   | 2.00 | ELF3     | 2.92 |          |      | WSB1     | 1.75 |
| H3F3B    | 1.97 | EFNA1    | 2.92 |          |      | ELK3     | 1.74 |
| Novel    | 1.93 | CD83     | 2.75 |          |      | EGLN1    | 1.73 |
| RNF32    | 1.86 | TNFAIP3  | 2.69 |          |      | PLOD2    | 1.69 |
| WSB1     | 1.85 | JUN      | 2.44 |          |      | ADM      | 1.68 |
| WSB1     | 1.82 | Novel    | 2.40 |          |      | CYLN2    | 1.67 |
| PRDX3    | 1.81 | PLAU     | 2.33 |          |      | PIM1     | 1.62 |
| CXCL1    | 1.79 | TNFAIP2  | 2.31 |          |      | SERPINB1 | 1.62 |
| MAIL     | 1.78 | EFNA1    | 2.29 |          |      |          |      |
| Novel    | 1.76 | Novel    | 2.28 |          |      |          |      |
| DC36     | 1.76 | CFLAR    | 2.27 |          |      |          |      |
| JUN      | 1.75 | PDGFβ    | 2.26 |          |      |          |      |
| Novel    | 1.75 | PLK3     | 1.93 |          |      |          |      |
| RAP2A    | 1.73 | EPHA2    | 1.89 |          |      |          |      |
| MAP3K7   | 1.73 | TIEG     | 1.85 |          |      |          |      |
| UBE2M    | 1.73 | EGR1     | 1.85 |          |      |          |      |
| PHLDA1   | 1.71 | SF1      | 1.82 |          |      |          |      |
| NCK1     | 1.70 | IFNγR2   | 1.81 |          |      |          |      |
| STK17A   | 1.70 | BIRC1    | 1.79 |          |      |          |      |
| SEC23A   | 1.70 | Novel    | 1.76 |          |      |          |      |
| DDX18    | 1.70 | DUSP5    | 1.73 |          |      |          |      |
| CCDC6    | 1.69 | ARRD1C3  | 1.71 |          |      |          |      |
| RAGE     | 1.69 | VMP1     | 1.71 |          |      |          |      |
| Novel    | 1.69 | CXCL1    | 1.71 |          |      |          |      |
| PCF11    | 1.69 | Novel    | 1.69 |          |      |          |      |
| Novel    | 1.69 | MAP3K8   | 1.67 |          |      |          |      |
| ETEA     | 1.68 | Novel    | 1.65 |          |      |          |      |
| NFS1     | 1.67 | ATP2     | 1.64 |          |      |          |      |
| PPA2     | 1.67 | FOSL2    | 1.64 |          |      |          |      |
| UBE2D3   | 1.67 | EGR1     | 1.61 |          |      |          |      |
| Novel    | 1.66 | Novel    | 1.60 |          |      |          |      |
| Novel    | 1.65 |          |      |          |      |          |      |

LoVo cells were treated with 2 μg/ml KF1B and 10 ng/ml TNFα for indicated times. Genes induced by KF1B at >1.6-fold ratio between control and treated cells are shown. The genes that were commonly induced by Nod1 and TNFα stimulation and those that are known to be induced by NF-κB, proinflammatory TNFα, and/or LPS (46) are underlined and bolded, respectively.

Types of immune cells into the peritoneal cavity after i.p. administration of the synthetic Nod1 ligand. 16 h after administration, Nod1 stimulation was found to induce recruitment of Gr1⁺ neutrophils but not lymphocytes, macrophages, or other cell types as determined by morphological (Fig. 6, A and B) and flow cytometric analyses (Fig. 6 C). The effect was Nod1 dependent in that the recruitment of neutrophils induced by KF1B was abolished in Nod1-deficient mice (Fig. 6).
FK1B did not increase the number of macrophages or lymphocytes in the peritoneal cavity (Fig. 6 B). The recruitment of neutrophils mediated through Nod1 stimulation is consistent with the induction of CXCLs by FK1B. To determine whether resident cells found in the peritoneal cavity respond to FK1B, we prepared intraperitoneal cells and stimulated them with the Nod1 ligand. We found no detectable secretion of CXCL1 after stimulation of FK1B even though the cells responded to LPS (Fig. 6 E). Notably, analysis of peritoneal cavity tissues that are rich in mesothelial cells revealed induction of CXCL1 expression after FK1B stimulation in vivo (Fig. 6 F). These results suggest that mesothelial cells and/or other cells present in the tissue from the peritoneal cavity are the main sources of CXCL1.

DISCUSSION

We previously demonstrated that Nod1 is essential for host response against iE-DAP–containing small molecules (5). These iE-DAP–containing molecules include intermediates and degradation products of PGN (5, 6, 12). In this paper, we show that the monomeric disaccharide tetrapeptide was Nod1 stimulatory, whereas the dimeric disaccharide tetrapeptide resulting from one linkage between the ε-amino residue in mesoDAP and the α-carboxyl residue in ε-Ala was not. This linkage bond is important for the cross-linking among PGN chains (24). The percentage of linked/free PGN chains varies among bacterial species and growth conditions in certain bacteria (24). For example, ~80% of the ε-amino acid residue of DAP remains free in Escherichia coli (24). Thus, our finding that cross-linking between DAP and ε-Ala eliminates Nod1-mediated host recognition suggests that the ability of bacterial PGN fragments to stimulate Nod1 varies depending on species and growth conditions of bacteria. Both hosts and bacteria have amidases that cleave the bond between the polysaccharide and oligopeptide chains of PGN, and bacteria also have enzymes that generate various oligopeptide species during the synthesis and remodeling of PGN (23). A tripeptide ε-Ala-iE-DAP was reported to possess a higher ability to stimulate Nod1 than dipeptide iQ-DAP using purified fractions (7). We confirmed the latter result by comparing the Nod1 stimulatory activity of ε-Ala-iE-DAP and ε-DAP using synthetic equivalents (Fig. 2 C). However, we found that the stimulatory activity of the tripeptide ε-Ala-iQ-DAP was less than that elicited by the dipeptide iQ-DAP (Fig. 2 D). Therefore, the association between NH2-terminal extension of the core structure and increased ability to stimulate Nod1 is not a general feature of Nod1 ligands.

Bacterial- and synthetic iE-DAP–containing molecules are known to induce innate and acquired immune responses (25). However, because of the relatively poor immunostimulatory ability of iE-DAP–containing molecules, compared with that of LPS and MDP-related molecules (see Fig. 4 D) (6, 19, 20), it has been difficult to investigate the role of Nod1 stimulation in immune responses. In this paper we developed acyl compounds that possess an enhanced ability to stimulate Nod1. These molecules, including myristoyl (C-14), palmitoyl (C-16) iE-DAP compounds (referred to as KF1B, KFC15, and KFC16, respectively), were found to exhibit a several hundredfold stronger ability to stimulate Nod1 than the original iE-DAP. Because these acyl residues naturally exist in host membrane lipids, their potent stimulatory ability could be explained by increased translocation across the plasma membrane and delivery into the cytosol through cellular machinery that may include lipid flippases or related factors (26). Using these compounds, we investigated the immune response induced upon Nod1 stimulation. We found that intestinal epithelial cell lines were highly responsive, whereas macrophages, DCs, and splenocytes did not respond to Nod1 ligands alone under our experimental conditions. These results are consistent with the tissue expression profile of Nod1 that showed high levels of Nod1 expression in epithelial tissues such as the intestine (5). Several genes induced by Nod1 stimulation, including CXCL1, CD83, and MBL2, are known to be involved in the recruitment of immune cells and complement factors after bacterial infection. Similarly, our analysis in mice revealed that secretion of CCL2 was induced in serum and multiple tissues upon Nod1 stimulation in vivo. These results suggest that Nod1 functions as a pathogen recognition receptor to induce expression of proteins that play a critical role in the early stages of the innate immune response.

Nod1 is an intracellular protein, and, thus, recognition of bacteria through Nod1 would signal potentially harmful invasion of epithelial surfaces such as that lining the gut. In the case of the intestine, the mucosa is exposed to a large concentration of commensal bacteria that express a wide array of TLR ligands. However, inappropriate innate recognition and inflammatory responses are avoided, at least in part, by the lack of TLR signaling in the surface intestinal epithelium (17). A model suggested by these results is that after invasion of the epithelium by pathogenic bacteria, TLR-positive innate immune cells are recruited, though Nod1–induced chemokines and stimulation of these cells results in the production of cytokines such as TNFα that amplify the host response. Thus, although both TLR and Nod proteins recognize bacterial products, they may play distinct roles in bacterial clearance. Intestinal epithelial cells are also likely to play an important role in this amplification loop of the host defense through the induction of genes that are unique to TNFα signaling. Comprehensive microarray analysis revealed that Nod1 and TNFα induced a different profile of gene expression that include both common and specific genes in epithelial cells. These observations suggest that primary and secondary responses against bacteria in intestinal epithelial cells are different. The genes induced by Nod1, but not TNFα, include TAK1 and Ikβζ, which are critical factors in TLR and IL-1R pathways (27–29). Co-stimulation with Nod1 and Nod2 enhances TLR signaling (6, 30). The enhancement of TLR signaling by Nod1 might be due, at least in part, to the induction of TAK1 and Ikβζ. Nod1 stimulation also induced several novel genes that have unknown functions. Further studies are required to reveal the
physiological role of these Nod1-responsive genes. The molecular basis that accounts for the induction of unique genes by Nod1 and TNFα signaling is unclear. A possible explanation is that differences in gene expression reflect differential activation of intracellular signaling molecules. For example, RICK, a downstream factor of Nod1, has been shown to activate NFκB through TRAF6, whereas TRAF2 is critical for TNFα signaling (31–33).

Nod1 gene variants have been recently associated with the development of asthma (34). Moreover, genetic variations in Nod1 and Nod2 are associated with increased susceptibility to Crohn’s disease (35–37). The Crohn’s disease-associated Nod2 mutations are defective in their response to muramyl dipeptide (38, 39). Because both Nod1 and Nod2 share the same downstream components for signaling, the defective response observed in cells harboring Nod2 mutations could be rescued by Nod1 stimulation. Thus, ligands such as KF1B could be useful for the development of novel approaches to treat Nod1- and Nod2-associated inflammatory diseases.
Materials and Methods

Bioassay for Nod1 ligand activity. Ligand-dependent NF-κB activation was determined using HEK293T cells transiently expressing Nod1, Nod2, or TLR4 and MD2 in the presence of pBxIV-luc and pEF1BOS-β-gal as described previously (6). In brief, HEK293T cells were transfected with expression plasmids by the calcium phosphate method, and cells were treated with medium containing various ligands 8 h after transfection. 24 h after transfection, ligand-dependent NF-κB activation was determined with a reporter assay. LoVo cells were transfected with pBxIV-luc and pEF1-BOS-β-gal (4) by Lipofectamine 2000 (Invitrogen), and cells were treated with medium containing 2 μg/ml KF1B, 0.2 μg/ml AcMTP, or 10 ng/ml TNFα 3 h after transfection. 24 h after transfection, ligand-dependent NF-κB activation was determined with a reporter assay.

Other materials. Highly purified fractions of whole soluble Cellosyl-treated PGN fragments (GlcNAc–MurNAc–l-Ala–γ-D-Glu–mesoDAP–d-Ala, shown as fraction 3 in reference 31, or dimeric GlcNAc–MurNAc–l-Ala–γ-D-Glu–mesoDAP–d-Ala cross-bridged between mesoDAP and d-Ala, shown as fraction 21 in reference 41) from Bacillus subtilis were prepared as described previously (41). In brief, dibenzyl-2,6-diaminopimelate (dibenzyl-DAP) was first connected to 2-chlorotrityl resin, and the remaining amino group of DAP was reacted with Fmoc-γ-D-Glu-OBn. After deprotection of Fmoc group, the acyl group (C-14, C-15, or C-16) was introduced to the liberated amino group to give the corresponding acylated iE-DAP on the resin. After cleavage from the resin with 10% trifluoroacetic acid, cleavage of the remaining protecting groups gave KF1B, KFC15, or KFC16, respectively. Synthetic compounds iE-DAP, iQ-DAP, CpG, and polyIC were described previously (5). Synthetic Ac–(6-O-stearoyl)–MurNAc–l-Ala–γ-D-Glu (AcMDP), AcMTP, and d-Ala–Gln–octadecyl ester (AcAq) were obtained from Bachem. E. coli O55:B5 LPS was purchased from Sigma–Aldrich. The LPS preparation that lacked contamination of substantial Nod1 and Nod2 stimulatory activity in the HEK293T bioassay was used in this study.

Cytokine assay. Human LoVo, SW620, and MonoMac6 cells were cultured and maintained in RPMI 1640 medium (Invitrogen). Macrophages and DCs were derived from BM using CSF1 and CSF2, respectively, as previously described (29). Cells were treated with the indicated amounts per milliliter of various ligands for the times shown in the figure legends. The cytokine and chemokine levels were determined by sandwich ELISA kits using specific antibodies (R&D Systems).

In vivo induction of cytokines and immune cell recruitment. 8-wk-old C57BL/6 (B6) WT and Nod1−/− mice in B6 background were maintained at the University of Michigan Animal Facility. B6 background Nod1−/− mice used in this study were generated by backcrossing at least six times with the parental B6 strain. Mice were administrated with the indicated amounts of various ligands by routes described in the figure legends. At the times indicated in the figures, sera and organs were collected from killed mice, and homogenates of organs were prepared by sonication with PBS (Invitrogen) containing 1% Triton X-100 and a mixture of protease inhibitors (Sigma–Aldrich), followed centrifugation at 100,000 g for 10 min. The cytokine and chemokine levels in sera and tissue homogenates from mice were determined by ELISA. For recruitment of immune cells at 24 h after i.p. administration of KF1B, peritoneal cells were collected from killed mice by PBS lavage. After centrifugation (Cytospin 2; Shandon Ltd.), cells were fixed and stained with a staining kit (Diff–; Dade Behring Inc.) according to the manufacturer’s recommendations. Cell types were determined by standard morphological features of stained cells. The number of GR1+ cells in 105 cells was determined by flow cytometry (FACSscan II; BD Biosciences) as previously described (41). The mouse studies were approved by the University of Michigan Committee on the Use and Care of Animals. For estimation of CXCL1 mRNA, total RNA was isolated from peritoneal tissue of WT mice using Trizol (Invitrogen). In brief, several 1-cm2 fragments of the peritoneal membrane were isolated and immediately homogenized with Trizol solution with and without KF1B stimulation. To assess mRNA expression, a semi-quantitative RT-PCR method was used, as previously described (42). CXCL1 and control GAPDH cDNA were synthesized from total RNA as previously described (43). Differential expression of 20,000 human genes (Invitrogen) was determined by hybridization of the probes with their cDNAs, followed by an analysis using a microarray scanner (GenePix 4000A; Molecular Devices) as described previously (43).

Real-time PCR and immunoblotting analysis of ligand-induced gene profiling change. Quantitative real-time PCR was performed using gene-specific primers (CD83, 5′-TTTAATGCGCCGCTGAAATG-3′, 5′-CACTCTAGAACAACTCCAGAGCT-3′ and 5′-CAAGCGAGACTGACTCCATCG-3′, GAPDH, 5′-AACGCCTCTCAGACGACC-3′ and 5′-CCCAGGACATCTCAGAC-3′) and subjected to 2% agarose electrophoresis.
and 5′-TTTAGGCCCCTAGCAAGGCTTGTG-3′; NFkBIA, 5′-CGCAGCGGGCTGAAAGG-3′ and 5′-ATGGCAATGCGAGAAG-3′; IL8, 5′-CAAGGGCAAGAATATCCGACT-3′ and 5′-TATCATTTCTAGAAACCCTATCGCA-3′; and CXCL1, 5′-CTC- AAATCTGCAATCCCCCATAGTTA-3′ and 5′-GGTGCCCTGTGAGTCTTCT-3′) and SYBR green dye with a real-time PCR system (model 7300; Applied Biosystems) as previously described (44, 45). The mean calculated quantity of the target gene for each sample was then divided by the mean calculated quantity of the housekeeping genes GAPDH and HMBS corresponding to each sample to give a relative expression of the target gene for the sample (46). All reactions were performed in duplicate. Immunoblotting analysis of CD83 in 50 μg total protein lysate from cells treated with 2 μg/ml KF1B, AcMTP or left alone was performed using anti-CD83 monoclonal antibody (BD Biosciences). Equal loading of proteins were confirmed by reversible staining with Ponceau S (Sigma-Aldrich) before immunodetection.

The authors are grateful to H. Takada for stimulating discussions and to J. Whitfield before immunodetection.

2. Inohara, N., M. Chamaillard, C. McDonald, and G. Nunez. 2005. Memorial Foundation for Medical and Pharmaceutical Research fellowship Pathology Foundation for International Exchange fellowship; and the Mochida of Education, Culture, Sports, Science and Technology (to K. Fukase); a Clinical (to N. Inohara, G. Núñez, and A.M. Chinnaiyan); grants from the Japanese Ministry of Health, Labour, and Welfare (to K. Takeshige).

4. Ting, J.P., and B.K. Davis. 2005. C A T E R P I L L E R : a novel gene family encoding a membrane-attached, C-terminal tandem repeat protein. Cell. 122:737–747.

11. Viala, J., C. Chaput, I.G. Boneca, A. Cardona, S.E. Girardin, A.P. Moran, R. Athman, S. Memet, M.R. Huerej, A.J. Coyle, et al. 2004. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5:1166–1174.

12. Girardin, S.E., I.G. Boneca, L.A. Carneiro, A. Antignac, M. Jehanno, J. Viala, K. Teda, M.K. Tada, A. Labigne, U. Takeuchi, et al. 2003. Nod1 detects a unique monomeric peptidoglycan from gram-negative bacterial peptidoglycan. Science. 300:1584–1587.

13. Inohara, N., T. Koseki, J. Lin, L. del Peso, P.C. Lucas, F.F. Chen, Y. Ogura, and G. Nunez. 2000. An induced proximity model for NF-kappaB activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 275:27823–27831.

14. Chin, A.I., P.W. Dempsey, K. Brunn, J.F. Miller, Y. Xu, and G. Cheng. 2002. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature. 416:190–194.

15. Kobayashi, K., N. Inohara, L.D. Hernandez, J.E. Galan, G. Nunez, T.K. Sato, D.O. Lobo, H.K. Hoshino, T. Kaisho, H. Kuwata, O. Takeuchi, et al. 2004. Nod1 detects a unique monomeric peptidoglycan from gram-negative bacterial peptidoglycan. Science. 300:1584–1587.

16. Guarner, F., and J.R. Malagelada. 2003. Gut flora in health and disease. Lancet. 361:512–519.

17. Abreu, M.T., M. Fukushima, and M. Arditi. 2005. TLR signaling in the gut in health and disease. J. Immunol. 174:4453–4460.

18. Hisamatsu, T., M. Suzuki, and D.K. Podolosky. 2003. Interferon-gamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells. J. Biol. Chem. 278:32962–32968.

19. Uchihara, A., S. Yang, Y. Fujimoto, K. Fukase, S. Kusumoto, K. Shihata, S. Sugawara, and H. Takada. 2005. Muramyl dipeptide and diaminopimelic acid-containing desmuramyl peptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in NOD2- and NOD1-dependent manner, respectively, in human monocyte cells in culture. Cell. Microbiol. 7:53–61.

20. Uchihara, A., Y. Sugawara, S. Kurata, Y. Fujimoto, K. Fukase, S. Kusumoto, Y. Satta, T. Sasano, S. Sugawara, and H. Takada. 2005. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Cell. Microbiol. 7:675–686.

21. Ogura, Y., N. Inohara, A. Benito, F.F. Chen, S. Yamaoka, and G. Nunez. 2001. Nod2, a Nod1/ Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 276:4812–4818.

22. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inanuma, S. Kusumoto, M. Hashimoto, et al. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J. Biol. Chem. 278:5509–5512.

23. Girardin, S.E., I.G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D.J. Philpott, and P.J. Sansonetti. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869–8872.

24. Schleifer, K.H., and O. Kandler. 1972. Peptidoglycan types of bacterial cell wall and their taxonomic implications. Bacterial. Rev. 36:407–477.

25. Goto, T., and H. Aoki. 1987. The immunomodulatory activity of acyl peptides. In Immunostimulants: Now and Tomorrow. I. Aruzuma and G. Jolles, editors. Japan Scientific Societies Press, Tokyo, 99–108.

26. Hvorup, R.N., B. Wannen, A.B. Chang, Y. Jiang, X.F. Zhou, and M.H. Saier. 2003. The multidrug/oligosaccharide/polysaccharide (MOP) exporter superfAMILY. Eur. J. Biochem. 270:799–813.

27. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-I kappaB inducible nuclear protein IkappaBzeta. Nature. 398:252–256.

28. Irie, T., T. Muta, and K. Takeshige. 2000. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappa B in lipopolysaccharide-stimulated macrophages. FEBS Lett. 467:160–164.

29. Kajimura, S., M. Sato, G. Takahasi, V. Umeda, T. Kashi, H. Kawai, O. Takeuchi, K. Takeshige, et al. 2004. Regulation of Toll/IL-1 receptor-mediated gene expression by the inducible nuclear protein IkappaBZeta. Nature. 430:218–222.

30. Kobayashi, K.S., M. Chamaillard, Y. Ogura, O. Henegar, N. Inohara, G. Nunez, and R.A. Flavell. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 307:731–734.
31. McCarthy, J.V., J. Ni, and V.M. Dixit. 1998. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. *J. Biol. Chem.* 273: 16968–16975.

32. Lu, C., A. Wang, M. Dorsch, J. Tian, K. Nagashima, A.J. Coyle, B. Jaffe, T.D. O’cain, and Y. Xu. 2005. Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. *J. Biol. Chem.* 280:16278–16283.

33. Sakurai, H., S. Suzuki, N. Kawasaki, H. Nakano, T. Okazaki, A. Chino, T. Doi, and I. Saiki. 2003. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. *J. Biol. Chem.* 278:36916–36923.

34. Hysi, P., M. Kabesch, M.F. Moffatt, M. Schedel, D. Carr, Y. Zhang, B. Boardman, E. von Mutius, S.K. Weiland, W. Leupold, et al. 2005. NOD1 variation, immunoglobulin E, and asthma. *Hum. Mol. Genet.* 14:935–941.

35. Hugot, J.P., M. Chamaillard, H. Zouali, S. Lesage, J.P. Cezard, J. Belaiche, S. Ahmer, C. Tysk, C.A. O’Morain, M. Gasull, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. *Nature* 411:599–603.

36. Ogura, Y., D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, R. Rams, H. Britton, T. Moran, R. Karulinus, R.H. Duerr, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. *Nature* 411:603–606.

37. McGovern, D.P., P. Hysi, T. Ahmad, D.A. van Heel, M.F. Moffatt, A. Carey, W.O. Cookson, and D.P. Jewell. 2005. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. *Hum. Mol. Genet.* 14: 1245–1250.

38. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, et al. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD 2. Implications for Crohn’s disease. *J. Biol. Chem.* 278:5509–5512.

39. Girardin, S.E., I.G. Boneca, J. Vila, M. Chamaillard, A. Lahigne, G. Thomas, D.J. Philpott, and P.J. Sansonetti. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J. Biol. Chem.* 278:8869–8872.

40. Atrih, A., G. Bacher, G. Allmaier, M.P. Williamson, and S.J. Foster. 1999. Analysis of peptidoglycan structure from vegetative cells of *Bacillus subtilis* 168 and role of PBP 5 in peptidoglycan maturation. *J. Bacteriol.* 181:3956–3966.

41. Coligan, J.E., A.M. Krusbeck, D.H. Margulis, E.M. Shevach, and W. Strober, editors. 1997. Current Protocols in Immunology. John Wiley & Sons, Inc., New York.

42. Gutierrez, O., C. Piacon, N. Inohara, A. Fontalba, Y. Ogura, F. Prosper, G. Nunez, and J.L. Fernandez-Luna. 2002. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappaB activation. *J. Biol. Chem.* 277:41701–41705.

43. Kumar-Sinha, C., S. Varambally, A. Sreekumar, and A.M. Chinnaiyan. 2002. Molecular cross-talk between the TRAIL and interferon signaling pathways. *J. Biol. Chem.* 277:575–585.

44. Kumar-Sinha, C., R.B. Shah, B. Laxman, S.A. Tomlins, J. Harwood, W. Schmitz, E. Conzelmann, M.G. Sanda, J.T. Wei, M.A. Rubin, and A.M. Chinnaiyan. 2004. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. *Am. J. Pathol.* 164:787–793.

45. Vandesompele, J., K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paep, and F. Speleman. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3:research0034.1–research0034.11.

46. Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene* 18:6853–6866.